Display options
Cite
van Luijn MM, van den Ancker W, van Ham SM, et al. Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology. 2015;3(12):e941737doi: 10.4161/21624011.2014.941737.
van Luijn, M. M., van den Ancker, W., van Ham, S. M., & van de Loosdrecht, A. A. (2014). Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology, 3(12), e941737. https://doi.org/10.4161/21624011.2014.941737
van Luijn, Marvin M, et al. "Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia." Oncoimmunology vol. 3,12 (2014): e941737. doi: https://doi.org/10.4161/21624011.2014.941737
van Luijn MM, van den Ancker W, van Ham SM, van de Loosdrecht AA. Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. Oncoimmunology. 2015 Jan 07;3(12):e941737. doi: 10.4161/21624011.2014.941737. eCollection 2014 Dec. PMID: 25964856; PMCID: PMC4353169.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Jan 07;3(12):e941737. doi: 10.4161/21624011.2014.941737. eCollection 2014 Dec.

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

Oncoimmunology

Marvin M van Luijn, Willemijn van den Ancker, S Marieke van Ham, Arjan A van de Loosdrecht

Affiliations

  1. Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands ; Department of Immunology; Erasmus MC University Medical Center ; Rotterdam, The Netherlands.
  2. Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands.
  3. Department of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam ; Amsterdam, The Netherlands.

PMID: 25964856 PMCID: PMC4353169 DOI: 10.4161/21624011.2014.941737

Abstract

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

Keywords: CD4+ T cells; HLA; immune escape; leukemia-associated phenotype; minimal residual disease

References

  1. J Immunother Cancer. 2013 Aug 27;1(13):null - PubMed
  2. Haematologica. 2008 Dec;93(12):1894-8 - PubMed
  3. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  4. Curr Opin Immunol. 2014 Feb;26:21-31 - PubMed
  5. PLoS One. 2012;7(4):e34649 - PubMed
  6. Cancer Res. 2011 Apr 1;71(7):2507-17 - PubMed
  7. Curr Opin Immunol. 2013 Apr;25(2):261-7 - PubMed
  8. J Clin Oncol. 2013 Nov 1;31(31):3889-97 - PubMed
  9. Leuk Res. 2014 Jun;38(6):691-3 - PubMed
  10. Nat Rev Immunol. 2006 Oct;6(10):715-27 - PubMed

Publication Types